ERBB2 and breast carcinoma: More recently, the FDA also granted olaparib approval for adjuvant treatment of BRCA-mutated, HER2-negative high-risk early breast cancer, previously treated with chemotherapy in neoadjuvant or adjuvant scenarios, based on the OlympiA (NCT02032823) clinical trial [101].